Research News

26 February 2025

USFDA accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy®

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application for Opdivo nivolumab plus Yervoy ipilimumab as a potential first-line treatment option for adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high MSI-H or mismatch repair deficient dMMR colorectal cancer

26 February 2025

UM School of Medicine Dermatology Researchers Discover New Skin Disease Using Innovative Diagnostic Platform

Utilizing a novel diagnostic test for peripheral blood immunophenotyping, researchers were able to identify the specific sources of inflammation triggering the novel skin disease and reverse symptoms with targeted treatments.

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no effective treatments beyond symptom management. Now a new study could pave the way for precision-medicine based diagnostic testing and targeted treatment.

26 February 2025

Hormones may have therapeutic potential to prevent wrinkles, hair graying

Hormones may be leveraged to treat and prevent signs of aging such as wrinkles and hair graying, according to a new study published in the EndocrineSociety journal Endocrine Reviews.

Until now, only a limited number of hormones, mainly topical retinoids (retinol and tretinoin) and estrogen which is typically used to treat side effects of menopause, have been used in clinical practice as anti-skin aging compounds. This study reviews a new class of hormones and their anti-aging properties.

26 February 2025

Research challenges our understanding of cancer predisposition

New findings question assumptions of cancer formation in individuals with the cancer-predisposition syndrome, neurofibromatosis type 1, and offer hope for a personalised approach to early cancer recognition including for those with similar conditions.

21 February 2025

New class of antimalarial drugs discovered

Malaria remains one of the greatest global health threats. In 2022, there were an estimated 247 million infections and over 600,000 deaths, mostly in sub-Saharan Africa. Innovative research approaches are therefore urgently needed to achieve long-term progress in prevention and treatment.

21 February 2025

Groundbreaking study shows potential of new mRNA vaccine to help fight tuberculosis

A new vaccine that boosts immunity against tuberculosis has been shown to be effective in pioneering pre-clinical trials, as part of a successful collaboration between three leading Australian research institutions. A study into the vaccine’s effectiveness, published in eBioMedicine, was led by experts from the Sydney Infectious Diseases Institute at University of Sydney, the Centenary Institute and the Monash Institute of Pharmaceutical Science at Monash University.

20 February 2025

Dysfunctional B Cells is a new Cancer Immunotherapy Target

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood, known as the tertiary lymphoid structure, where they become frustratingly dysfunctional when in close contact with tumors.

20 February 2025

New Therapy May Effectively Control HIV in Uganda

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

18 February 2025

Stanford researchers identify biological pathways associated with inherited cancer risk

Thousands of single changes in the nucleotides that make up the human genome have been associated with an increased risk of developing cancer. But until now, its not been clear which are directly responsible for the uncontrolled cellular growth that is the hallmark of the disease and which are simply coincidences or minor players.

17 February 2025

Olpasiran associated with reducing bad cholesterol in Cardiovascular Disease

The RNA inhibitor olpasiran significantly reduces a type of bad cholesterol thats associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai researcher of a phase 2 trial. The study reported that higher doses of olpasiran lowered the type of cholesterol called lipoprotein a by more than 95 percent in participants with atherosclerotic cardiovascular disease.

Search

USFDA accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy®

RECOMMENDED POSTS

Subscribe with us

Jobs by Category